Table 3.

Summary of treatment emergent adverse events.

	10 μg (N=5) Subjects (%) Events	30 μg (N=4) Subjects (%) Events	100 μg (N=4) Subjects (%) Events	300 μg (N=4) Subjects (%) Events	1 mg (N=5) Subjects (%) Events
At least one TEAE	5 (100.0%) 7	1 (25.0%) 2	3 (75.0%) 5	2 (50.0%) 2	4 (80.0%) 19
At least one Severe TEAE	0 (0.0%) 0	0 (0.0%) 0	0 (0.0%) 0	0 (0.0%) 0	1 (20.0%) 3
At least one Drug-Related AE[1]	3 (60.0%) 4	0 (0.0%) 0	1 (25.0%) 1	1 (25.0%) 1	4 (80.0%) 16
At least one TESAE	0 (0.0%) 0	0 (0.0%) 0	0 (0.0%) 0	0 (0.0%) 0	1 (20.0%) 1

^[1]Drug-related is defined as unlikely, possibly, probably or definitely related to study drug.